| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5987361 | The Journal of Heart and Lung Transplantation | 2014 | 9 Pages |
Abstract
Although reliable assessments of safety and efficacy require a long-term randomized trial, the addition of sildenafil to background intravenous epoprostenol therapy appeared generally to be well tolerated in PAH patients.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Gérald MD, Lewis J. MD, Nazzareno MD, Robyn J. MD, Thomas R. PhD, Adaani MD, Peter MD, Mordechai R. MD, Marjana MD, Gary R. MSc, Olivier MD, PhD, David B. MD, on behalf of the PACES Study Group on behalf of the PACES Study Group,